Immuneering Corp Stock Price, News & Analysis

Immuneering Corporation (NASDAQ: IMRX) announced its financial results for Q2 2022, reporting a net loss of $11.5 million, or $0.44 per share, up from $8.0 million, or $1.61 per share, in Q2 2021. The company holds $128.1 million in cash and equivalents, sufficient to fund operations until Q3 2024. Upcoming milestones include filing an IND for IMM-1-104, targeting RAS mutation-driven tumors, this quarter, and the first patient enrollment in Q4 2022. Additionally, an IND for IMM-6-415 is expected in 2023.

Immuneering Corporation (Nasdaq: IMRX) announced its participation at the William Blair Biotech Focus Conference 2022 on July 13, 2022. CEO Ben Zeskind will be part of a panel discussing pre-clinical data related to the company’s lead product candidate, IMM-1-104, which targets pan-KRAS/NRAS activity in advanced solid tumors. Immuneering’s innovative approach combines translational bioinformatics with unique drug design strategies to enhance treatment outcomes for cancer patients, leveraging its proprietary 3D tumor modeling and bioinformatics platforms.

Immuneering Corporation (NASDAQ: IMRX) announced preclinical data for its dual-MEK inhibitor, IMM-1-104, showing significant tumor growth inhibition (TGI) in pancreatic cancer models with KRAS mutations. The drug demonstrated TGI of 49-84% against KRAS-G12V mutant tumors, outperforming existing treatments like sotorasib and adagrasib. The company plans to submit an IND in Q3 2022 and start Phase 1 trials in Q4 2022. These findings suggest IMM-1-104 has potential broad activity against various tumors driven by MAPK mutations, positioning it favorably in oncology.

Immuneering Corporation (NASDAQ: IMRX) will present its business strategy and pipeline at the Jefferies Healthcare Conference on June 8, 2022, and the H.C. Wainwright Global Investment Conference from May 24-26, 2022. Ben Zeskind, CEO, and Brett Hall, CSO, will lead the Jefferies presentation, which is a moderated fireside chat. The presentation will be available for live streaming and archived for 30 days. Immuneering focuses on developing oncology and neuroscience products using a unique translational bioinformatics platform, with key candidates including IMM-1-104 and IMM-6-415.

Immuneering Corporation (NASDAQ: IMRX) announced its first quarter 2022 financial results, reporting a net loss of $12.9 million ($0.49 per share). The company has $137.8 million in cash, expected to provide a runway into Q3 2024. Key developments include the anticipated IND filing for IMM-1-104 in Q3 2022 and patient enrollment in Q4 2022, with encouraging preclinical results across various tumor models. R&D expenses rose to $9.1 million, reflecting increased preclinical costs. Additionally, the second IND for IMM-6-415 is expected in 2023.

Immuneering Corporation (Nasdaq: IMRX) announced management's participation in Citi’s Biopharma VIRTUAL Co-Panel Day on May 18, 2022, focusing on software, artificial intelligence, and bioinformatics in drug development. The event will feature Ben Zeskind, Ph.D., Co-Founder and CEO, and will be webcast live at 10:00 am ET.

Immuneering aims to improve patient outcomes with a unique oncology and neuroscience pipeline. Its lead candidate, IMM-1-104, targets advanced solid tumors with RAS mutations, utilizing a proprietary 3D tumor modeling platform.

Immuneering Corporation (Nasdaq: IMRX) announced its participation in Piper Sandler’s AI/ML Investor Conference on April 1, 2022, where CEO Ben Zeskind will discuss advancements in drug development using artificial intelligence and bioinformatics. Immuneering harnesses over a decade of experience in translational bioinformatics to enhance oncology and neuroscience therapies. Its lead candidate, IMM-1-104, is designed for treating advanced solid tumors in patients with RAS mutations by targeting the MAPK pathway. The company is also advancing other oncology and neuroscience programs.

Immuneering Corporation (Nasdaq: IMRX) announces its participation in the 21st Annual Needham Virtual Healthcare Conference, scheduled for April 11-14, 2022. Management, including CEO Ben Zeskind and CFO Biren Amin, will present insights on the company's oncology pipeline and business strategy. The presentation will occur on April 12 from 3:45-4:25 PM ET. Immuneering's lead candidate, IMM-1-104, is a dual-MEK inhibitor targeting RAS mutations in advanced tumors, aimed at sparing healthy cells. The company uses a proprietary bioinformatics platform to advance its pipeline.

Immuneering Corporation (Nasdaq: IMRX) reported financial results for Q4 and full year 2021, highlighting significant advancements in their lead product candidate, IMM-1-104. This candidate shows broad activity against various tumor models with activating mutations. The company holds $150.2 million in cash, ensuring funding through Q3 2024. Notably, they expect to file an IND for IMM-1-104 in Q3 2022. Research and development expenses increased to $26.5 million for 2021, primarily due to preclinical initiatives. The net loss for the year was $33.5 million, or $2.46 per share.